Brandes Investment Partners 13F: Cuts BDX Stake by $7.4M
Brandes Investment Partners cut its position in Becton, Dickinson and Company by 48,583 shares during the period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brandes Investment Partners sold 48,583 shares from its stake in Becton, Dickinson and Company ($BDX), a 3.11% decrease, according to a 13F filing with the SEC dated May 15, 2026. It reported 1,515,604 shares worth $229.36 million at the end of the quarter.
Since the filing, $BDX is up 2.9% after 1 week, up 2.1% after 1 month and up 35.4% to date (from the $141.63 close on May 15, 2026).
Find the original: Brandes Investment Partners 13F filings on SEC EDGAR
BDX
Becton, Dickinson and Company
Key Points
- Brandes Investment Partners trimmed its stake in Becton, Dickinson and Company NYSE:BDX by 3.1%, shedding 48,583 shares to end with 1,515,604 shares valued at roughly $229.3 million according to a Form 13F filing.
- Becton, Dickinson shares traded near $151.33 on Saturday, sitting well below their 52-week high of $193.07 while carrying a trailing P/E ratio of 31.3.
- Company insiders recently reported transactions, including executive sales by Michael Feld and Garrison Michael David under planned trading schedules.
Get $BDX trade alerts by text
We text you when insiders, Congress or big funds trade $BDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Becton, Dickinson and Company alert may contain errors. Disclosures
Brandes Investment Partners Adjusts Becton, Dickinson Position
Brandes Investment Partners trimmed its holdings in Becton, Dickinson and Company NYSE:BDX by 3.1% during the period, according to a recent Form 13F filing with the Securities and Exchange Commission. The fund sold off 48,583 shares, bringing its total ownership to 1,515,604 shares. Based on the cost basis and reporting period metrics, the remaining stake carries an estimated value of $229.3 million. This filing captures portfolio adjustments as of the reporting date and may not reflect the firm's current holdings today.
Becton, Dickinson Stock Trades Near Lower Half of Yearly Range
Shares of Becton, Dickinson changed hands around $151.33 on Saturday. The stock moves within a 52-week range spanning from a low of $127.59 to a high of $193.07. The medical device maker features a trailing price-to-earnings ratio of 31.3 and a forward P/E of 13.6, with a market capitalization sitting near $49.2 billion.
Recent Earnings and Financial Health
Becton, Dickinson reported annual revenue of $22.48 billion, representing a 5.4% growth rate. The healthcare company posted earnings of $5.77 per share alongside a net margin of 4.2% and a return on equity of 6.6%. The company is scheduled to release its next quarterly financial results on November 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 3.5%. Revenue met estimates.
-
Profit surprise
EBITDA missed by 86 percent. Operating income missed by 91 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target raises, 1 target cut.
-
Earnings quality
Gross margin up 2.9 points. Operating margin down 8.4 points. Positive free cash flow.
Earnings Call Summary
BDX closed its Waters separation today and reported stronger-than-expected first-quarter results with $5.3 billion in revenue and $2.91 in earnings per share. Growth areas like PureWick and biologic drug delivery are performing well with double-digit gains, though China vaccines and Alaris remain headwinds. Management is investing aggressively in high-growth categories and has already captured 80 GLP-1 molecules in drug delivery devices.
Guidance BDX expects about $12.50 in adjusted earnings per share for the full year, roughly 6 percent growth after tariffs. Management said low single-digit revenue growth is on track. They plan to return $4 billion from the Waters separation through buybacks and debt paydown.
Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.
Dividend Commitments to Shareholders
The company pays an annual dividend rate of $4.20 per share, which translates to a dividend yield of 2.3% based on recent trading levels. This payout is supported by a dividend payout ratio of 72.5%.
Executive Insider Transactions
Company insiders have recently disclosed routine stock dispositions. On June 26, 2026, EVP and Chief Revenue Officer Michael Feld sold 75 shares at an average price of $152.80 for a total of $11,460 under a pre-arranged plan. Earlier on June 24, 2026, EVP Garrison Michael David sold 1,100 shares at $145.66 per share, totaling $160,226, also through a planned trading arrangement.
Wall Street Analyst Forecasts and Consensus
Analyst firms continue to review their outlooks for the medical supplier. On October 7, 2026, Barclays initiated coverage with an Underweight rating and a $165.00 price target. Earlier in August, B of A Securities maintained its Neutral rating while lifting its target to $200.00, and Citigroup kept a Buy rating with a target of $204.00. Across the broader analyst community, the stock holds a consensus Buy recommendation and an average price target of $195.67 from twelve covering opinions.
Inside the Operations of Becton, Dickinson
Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company develops and sells medical supplies, diagnostic systems, and laboratory equipment for healthcare providers worldwide. Founded in 1897, the company operates across multiple segments, offering products ranging from vascular access devices to automated specimen collection tools.
What to Watch Next for the Stock
Investors tracking Becton, Dickinson will look ahead to the company's next earnings report in November and subsequent institutional filings to gauge whether other large asset managers adjust their positions. Because 13F reports look backward, these disclosures show past portfolio choices rather than live trading activity.
Related Filing Alerts
Source: Brandes Investment Partners's 13F filing on $BDX (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Brandes Investment Partners 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts